$696,665,954

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

ACTION DATE—·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50120C00092_7505_-NONE-_-NONE-

Award description

US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Funds domestic advanced manufacturing of active pharmaceutical ingredients for COVID-19 medicines and future pandemic threats.

Sub-sectors

pharmaceutical-manufacturingapi-productionpandemic-preparedness

Why this matters

Establishes U.S. domestic capacity for critical medicine production to reduce dependence on foreign suppliers during health emergencies.

Supply-chain signal

Signals intent to build redundant domestic API manufacturing capability, reducing reliance on international pharmaceutical supply chains.

U.S.–China competition angle

Addresses vulnerability to supply chain disruptions from China, which dominates global API manufacturing for essential medicines.

Generated by award_classification v1.0.0 via claude-haiku-4-5-20251001 on 2026-05-13. Cost: $0.001319.

Period of performance

Start

2020-05-18

End

2027-01-13

Status

activein 244 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50120C00092_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.